57,018 views
Helping us understand attention deficit disorder (ADHD): the challenges of innovative research at the University of Strasbourg. By Michael Reber Inserm researcher at the Institute of Cellular and Integrative Neurosciences CNRS – University of Strasbourg (http://inci.u-strasbg.fr/tdah) Attention Deficit Hyperactivity Disorder (ADHD) is a brain development disorder that affects 3% to 5% of children in France. 60% of them retain symptoms into adulthood. Michael Reber's team demonstrated in 2015 that hypersensitivity to visual stimulation in a laboratory model was associated with ADHD symptoms and also with a strong increase in noradrenaline (neurotransmitter) in a specific structure of the brain, the superior colliculus, involved in the control of visual attention in mammals, including humans. These discoveries were then massively relayed in the media (Nouvel Obs, DNA, le temps, Sciences et Avenir, Biofutur, etc.). See the full press review: http://campagne.unistra.fr/uploads/Re... The scientific question at the heart of the research: what are the effects of methylphenidate (active molecule of Ritalin®, Concerta®, Quasym®, etc.) on visual hypersensitivity and in particular on the increase in noradrenaline? To answer this question, Michael Reber's team will use cutting-edge technology, mass spectrometry, to better understand the effect of methylphenidate depending on the doses administered and therefore improve the drug management of patients with ADHD. To support Michael Reber's research, make a donation: http://campagne.unistra.fr/TDAH